Clinical Trials

An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences